MoonLake Immunotherapeutics (MLTX) reported a Q1 net loss Sunday of $0.98 per diluted share, widening from a loss of $0.63 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.98.

As of March 31, 2026, the company held $357.9 million in cash, cash equivalents and short-term marketable debt securities. It added that it expects to have sufficient capital to fund its operating expenses and capital expenditure requirements to the end of 2027.